ArticleWorld journal of experimental medicine2025
Clinical significance of differential plasma proteins levels in the diagnosis of epithelial ovarian cancer.
Article in World journal of experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOvarian cancer (OC) is the most lethal gynecological cancer among females, and its early diagnosis could help for better outcomes of the patients.
aimTo investigate the utility of serum insulin-like growth factors-binding proteins 2 (IGFBP2), secreted phosphoprotein 1 (SPP1), thrombospondin 1 protein (TSP1) and D-dimer levels in addition to currently used biomarkers [cancer antigen 125 (CA125) and human epididymis protein 4 (HE4)] in the diagnosis of epithelial OC (EOC).
methodsThis is a case-control study that included fifty females diagnosed with EOC, 10 females with benign ovarian masses recruited from the Egyptian National Cancer Institute, and 30 healthy females as a control group. All subjects were assessed for serum HE4, CA125, IGFBP2, TSP1 and SPP1 measurement by enzyme-linkedimmunosorbent assay.
resultsThere was a statistically significant difference in serum levels between EOC, benign ovarian masses, and healthy control groups regarding CA125 and SPP1 (
conclusionSPP1 may be a potential marker for the differentiation between benign and malignant ovarian masses, while IGFBP2 can differentiate between healthy females and females with ovarian masses. Combining SPP1 with CA125 or TSP1 provides high sensitivity and specificity for the detection of EOC patients
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.